Hemiplegia, Paraplegia G81, G820, G821, G822
Prostate Operation Insurance claims procedure codes
Comorbidities
Charlson Comorbidity Index ICD-10 codes for congestive heart failure, peripheral vascular disease, dementia, pulmonary disease, connective tissue disorder, peptic ulcer, liver disease, renal disease, severe liver disease, and HIV.
Hypertension
Blood pressure greater than SBP 140 mmHg or DBP 90 mmHg measured at the latest health screening before the index date. Diabetes E10, E11, E12, E13, E14 plus any prescription of drugs used for treatment of diabetes, or 126 mg/dL or higher fasting blood glucose measured at the latest health screening before the index date.
High cholesterol 240 mg/dL or higher total cholesterol measured at the latest health screening before the index date. 
Benign Prostatic Hyperplasia Patient Subcohort

Individualized index date 4 years after BPH diagnosis
Abbreviations: 5ARI, 5-alpha reductase inhibitor; cDDD, cumulative daily defined dose; BPH, benign prostatic hyperplasia. † Alpha-blocker, HMG-CoA reductase inhibitor, metformin, aspirin, and non-aspirin NSAID. * Age, body mass index, smoking habit, alcohol consumption frequency, exercise frequency, quartiles of socioeconomic status, number of outpatient visits, angina, hypertension, diabetes, high cholesterol, acute urinary retention, benign prostatic hyperplasia, atrial fibrillation/flutter, Charleson Comorbidity Index (including congestive heart failure, peripheral vascular disease, dementia, pulmonary disease, connective tissue disorder, peptic ulcer, liver disease, renal disease, severe liver disease, and HIV). -value<0.001 ) adjusted for age, hypertension, diabetes, high cholesterol, body mass index, smoking habit, alcohol consumption frequency, exercise frequency, socioeconomic status in quartiles, benign prostatic hyperplasia, acute urinary retention, atrial fibrillation or flutter, angina, Charlson Comorbidity Index, outpatient visits, alpha-blocker use, aspirin use, NSAID use, HMG-CoA reductase inhibitor use, and year of first 5ARI prescription or year of BPH diagnosis (for BPH patient subcohort). † Using a multivariate cox proportional hazard (Wald χ 2 test P-value<0.001) adjusted for age, hypertension, diabetes, high cholesterol, body mass index, smoking habit, alcohol consumption frequency, exercise frequency, socioeconomic status in quartiles, acute urinary retention, atrial fibrillation or flutter, angina, Charlson Comorbidity Index, outpatient visits, alpha-blocker use, aspirin use, NSAID use, and HMG-CoA reductase inhibitor use. Main cohort was additionally adjusted for benign prostatic hyperplasia and year of first 5ARI prescription; BPH patient subcohort, the year of BPH diagnosis.
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